Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
13 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05879926 | Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25(OFSET) | recruiting | Phase 3 | 3,960 | NRG OncologyOTHER | 8 | Sep 2, 2026 | clinicaltrials |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response(TRIPLE-SWITCH) | recruiting | Phase 3 | 830 | Canadian Cancer Trials Group |
| 4 |
| Jul 14, 2026 |
| clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT02563054 | A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer | completed | Phase 3 | 316 | Hoffmann-La RocheINDUSTRY | 14 | Nov 2, 2016 | clinicaltrials |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | completed | Phase 3 | 1,021 | Hoffmann-La RocheINDUSTRY | 37 | Jun 10, 2016 | clinicaltrials |
| NCT00391092 | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 3 | 424 | Hoffmann-La RocheINDUSTRY | 16 | Aug 28, 2015 | clinicaltrials |
| NCT00312208 | Docetaxel in Breast Cancer | completed | Phase 3 | 3,299 | SanofiINDUSTRY | 37 | Dec 30, 2013 | clinicaltrials |
| NCT00262067 | A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) | unknown | Phase 3 | 1,237 | Genentech, Inc.INDUSTRY | 22 | Dec 13, 2013 | clinicaltrials |
| NCT00688740 | Docetaxel in Node Positive Adjuvant Breast Cancer(TAX316) | completed | Phase 3 | 1,491 | SanofiINDUSTRY | 20 | Feb 16, 2011 | clinicaltrials |
| NCT00401323 | Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 568 | SanofiINDUSTRY | 20 | Jan 20, 2011 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials